Atomo Diagnostics Ltd.ASX: AT1

Atomo & Access Bio sign deal for rapid antigen test

· Issued by Atomo Diagnostics Ltd.

Filed with ASX · · 3 pages · English

with Access Bio LLC, (Access), previously announced to ASX on 28 July 2020. Under the expanded partnership, Atomo will have non-exclusive rights to market and distribute COVID-19 Antigen Test, subject to obtaining the required regulatory approvals in each jurisdiction. The Atomo COVID-19 rapid antigen test is a nasopharyngeal swab test designed to screen for antigens produced in response to COVID-

Atomo Diagnostics Ltd. on 6ix

Story so far

Earlier from Atomo Diagnostics

Later from Atomo Diagnostics

All Atomo Diagnostics news releases